Essex Investment Management Co. LLC lifted its holdings in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 116.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,494 shares of the specialty pharmaceutical company’s stock after buying an additional 18,535 shares during the period. Essex Investment Management Co. LLC owned about 0.22% of Cumberland Pharmaceuticals worth $244,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of CPIX. Stonepine Capital Management LLC raised its holdings in shares of Cumberland Pharmaceuticals by 49.9% during the 2nd quarter. Stonepine Capital Management LLC now owns 1,109,167 shares of the specialty pharmaceutical company’s stock worth $7,764,000 after buying an additional 369,250 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Cumberland Pharmaceuticals during the 1st quarter worth $165,000. Renaissance Technologies LLC raised its holdings in shares of Cumberland Pharmaceuticals by 5.2% during the 1st quarter. Renaissance Technologies LLC now owns 270,240 shares of the specialty pharmaceutical company’s stock worth $1,875,000 after buying an additional 13,240 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Cumberland Pharmaceuticals by 1.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 863,819 shares of the specialty pharmaceutical company’s stock worth $5,995,000 after buying an additional 10,843 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Cumberland Pharmaceuticals by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 298,635 shares of the specialty pharmaceutical company’s stock worth $2,111,000 after purchasing an additional 1,180 shares in the last quarter. 34.40% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/cumberland-pharmaceuticals-inc-cpix-shares-bought-by-essex-investment-management-co-llc/1682914.html.

Cumberland Pharmaceuticals Inc. (NASDAQ CPIX) opened at $7.49 on Monday. Cumberland Pharmaceuticals Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $7.77. The company has a quick ratio of 4.45, a current ratio of 4.88 and a debt-to-equity ratio of 0.10.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 0.13% and a negative net margin of 19.57%. The firm had revenue of $8.67 million during the quarter.

Cumberland Pharmaceuticals Profile

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Institutional Ownership by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.